Back to Search Start Over

Protocol for a Randomized, Crossover Trial to Decrease Time in Hypoglycemia by Combined Intervention of the Usage of Intermittent-Scanning Continuous Glucose Monitoring Device and the Structured Education Regarding its Usage: Effect of Intermittent-Scanning Continuous Glucose Monitoring to Glycemic Control Including Hypoglycemia and Quality of Life of Patients with Type 1 Diabetes Mellitus Study (ISCHIA Study)

Authors :
Shota, Suzuki
Atsuhito, Tone
Takashi, Murata
Kunihiro, Nishimura
Yoshihiro, Miyamoto
Naoki, Sakane
Noriko, Satoh-Asahara
Masao, Toyoda
Yushi, Hirota
Munehide, Matsuhisa
Akio, Kuroda
Ken, Kato
Ryuji, Kouyama
Junnosuke, Miura
Akiko, Suganuma
Tsutomu, Tomita
Michio, Noguchi
Cheol, Son
Masato, Kasahara
Yukie, Ito
Shu, Kasama
Kiminori, Hosoda
Source :
The Tokai journal of experimental and clinical medicine. 46(2)
Publication Year :
2020

Abstract

Intermittent-scanning continuous glucose monitoring (isCGM) is widely used in type 1 diabetes (T1D) patients; however, the education required to prevent hypoglycemia by using isCGM is not established. This study examines the combined effect of isCGM device usage and the education to reduce the time in hypoglycemia in comparison to conventional self-monitoring of blood glucose (SMBG).The Effect of Intermittent-Scanning Continuous Glucose Monitoring to Glycemic Control Including Hypoglycemia and Quality of Life of Patients with Type 1 Diabetes Mellitus Study (ISCHIA Study), a randomized, crossover trial, enrolls 104 T1D patients (age, 20-74 years) with T1D. Participants are randomized to use isCGM combined with structured education (Intervention period) or SMBG (Control period) for 84 days, followed by the other for a further 84 days. During the Intervention period, participants have access to the sensor glucose levels and trend arrow of the device. During the Control period, participants conduct SMBG at least three times a day, and retrospective CGM is used to record the blinded sensor glucose levels. The primary endpoint is the decrease of time in hypoglycemia (70 mg/dL) per day (hour/day) during the Intervention period compared with the Control period. The secondary endpoints include other indices of glycemic control, glycoalbumin, accuracy of isCGM, diabetes-related quality of life (QOL), adherence, and cost-effectiveness. The study protocol has received Certified Review Board (CRB) approval from National Hospital Organization Osaka National Hospital (N2018002, Feb 14, 2019). This study is carried out in accordance with the Declaration of Helsinki and the Clinical Trials Act. The findings will be published in peer-reviewed journals.The ISCHIA study will contribute to the standardization of patient education regarding the prevention of hypoglycemia by using isCGM.

Details

ISSN :
21852243
Volume :
46
Issue :
2
Database :
OpenAIRE
Journal :
The Tokai journal of experimental and clinical medicine
Accession number :
edsair.pmid..........7974330c105976050d51f4e5e5f235b4